Dasatrue 70 mg (1 pack / 60 tabs)

Dasatinib (Dasatrue 70mg) is indicated for the treatment of: Newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), Chronic phase, accelerated phase, or myeloid or lymphoid blast phase Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. As an anticancer medication, Dasatinib belongs to the class of tyrosine kinase inhibitors.